Quality of Evidence:
Coadministration has not been studied. Moxifloxacin is mainly metabolised by glucuronidation by UGT1A1 and concentrations may decrease due to induction of UGT1A1 by ritonavir. In addition caution should be exercised as both drugs have risks of QT prolongation and/or TdP on the CredibleMeds.org website (possible risk for lopinavir; known risk for moxifloxacin). If coadministration is needed, use with extreme caution including ECG monitoring.
Particular caution must be used when prescribing Kaletra and medicinal products known to induce QT interval prolongation. Indeed, Kaletra could increase concentrations of the co-administered medicinal products and this may result in an increase of their associated cardiac adverse events. Cardiac events have been reported with Kaletra in preclinical studies; therefore, the potential cardiac effects of Kaletra cannot be currently ruled out. Kaletra Summary of Product Characteristics, AbbVie Ltd, January 2021.
View all available interactions with
Lopinavir/ritonavir (LPV/r) by clicking